Back

Efficacy and safety of alirocumab in patients with multiple manifestations of cardiovascular disease (CVD): a post-hoc analysis of ODYSSEY program

28 August 2016 (10:40 - 10:47)
Organised by:
Congress Presentation Part of: Lipids and platelets Lipids ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Inhibition of lipopolysaccharide induced gene expression by HDL from healthy subjects and patients with acute myocardial infarction
Assistant Professor S. Imaizumi (Fukuoka, JP)
Abstract
Presentation thumbnail
Association of the postprandial chylomicron triglyceride/apoB index and cardiovascular events
Doctor C. Werner (Homburg, DE)
Abstract Slides
Presentation thumbnail
Malondialdehyde assay in evaluation of aspirin antiplatelet effects
Mrs L. Dannenberg (Duesseldorf, DE)
Abstract Slides
Presentation thumbnail
C2238 atrial natriuretic peptide molecular variant determines an increased platelet aggregation through the activation of NOX2 and the reduction of cAMP
Assistant Professor S. Sciarretta (Rome, IT)
Abstract
Presentation thumbnail
Impact of alirocumab on Lp(a) in individuals with and without moderate CKD
Professor P. Toth (Baltimore, US)
Abstract Slides

Access the full session

Session thumbnail
Lipids and platelets

The Event

Event poster

ESC Congress 2016

28 August 2016 10:40 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources